The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward
Alexis R Steinmetz1, Sharada Mokkapati1, David McConkey2
1Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background:
The intravesical gene therapy nadofaragene firadenovec (rAd-IFNα/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene therapy developed for bladder cancer. This non-replicating recombinant adenovirus vector delivers a copy of the human interferon alpha-2b gene into urothelial and tumor cells, causing them to express this pleotropic cytokine with potent antitumor effects.
Objective:
To provide a historical overview describing how several decades of preclinical and clinical studies investigating the role of interferon in the treatment of bladder cancer ultimately led to the development of gene therapy with nadofaragene for NMIBC.
Methods:
We conducted a review of the literature using PubMed, Google Scholar, and ClinicalTrials.gov to summarize our knowledge of the evolution of interferon-based therapy in NMIBC.
Results:
The FDA approval of this therapy represents an important landmark in urologic oncology and several decades of research dedicated to the study of interferon's direct and indirect antitumor properties in NMIBC. The data gathered from the phase 1, 2, and 3 clinical trials continue to provide additional insights into the precise mechanisms underlying both the efficacy of and resistance to nadofaragene.
Conclusions:
Nadofaragene leverages the cytotoxic, anti-angiogenic, and immune-modulatory roles of interferon to effectively treat NMIBC that is resistant to BCG. Ongoing studies of resistance mechanisms and prognostic biomarkers have been promising; these will ultimately improve patient selection and allow for the modulation of factors in the tumor or immune microenvironment to further increase therapeutic response.
Insights
Nadofaragene firadenovec is a novel gene therapy for BCG-unresponsive non-muscle invasive bladder cancer. This landmark treatment harnesses interferon's antitumor properties, offering a new option for patients with difficult-to-treat bladder cancer.
Area of Science:
- Urologic Oncology
- Gene Therapy
- Cancer Treatment
Background:
- Nadofaragene firadenovec (rAd-IFNα/Syn3) is the first gene therapy approved for bladder cancer (2022).
- It targets non-muscle invasive bladder cancer (NMIBC) resistant to Bacillus Calmette-Guérin (BCG) treatment.
- The therapy utilizes a recombinant adenovirus vector to deliver the human interferon alpha-2b gene, inducing antitumor effects.
Purpose of the Study:
- To provide a historical overview of interferon's role in bladder cancer treatment.
- To trace the development of nadofaragene gene therapy for NMIBC.
- To contextualize the FDA approval within decades of research.
Main Methods:
- Literature review using PubMed, Google Scholar, and ClinicalTrials.gov.
- Summarization of knowledge on interferon-based therapy evolution in NMIBC.
- Analysis of historical preclinical and clinical data.
Main Results:
- FDA approval of nadofaragene marks a significant milestone in urologic oncology.
- Ongoing clinical trials (Phase 1, 2, 3) provide insights into efficacy and resistance mechanisms.
- Interferon demonstrates direct and indirect antitumor properties in NMIBC.
Conclusions:
- Nadofaragene effectively treats BCG-resistant NMIBC by utilizing interferon's cytotoxic, anti-angiogenic, and immune-modulatory functions.
- Further research into resistance mechanisms and biomarkers aims to improve patient selection.
- Modulating the tumor or immune microenvironment may enhance therapeutic response.
Related Concept Videos
02:56The Fossil Record
03:00Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
02:55The Nucleolus
02:05Gene Evolution - Fast or Slow?
In contrast, regions which code...
02:37Gene Duplication and Divergence
The duplicated copies of the gene are called Paralogs. Paralogs with similar sequences and functions form a gene family. Across several species, a large number of gene families are...